Guardian Pharmacy Services Inc-A 2024年度报告

(Mark One)☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the fiscal year endedDecember 31,2024OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromtoCommission file number001-42284 Guardian Pharmacy Services, Inc.(Exact name of Registrant as specified in its charter) 300 Galleria Parkway SESuite 800Atlanta,Georgia30339(Address of Principal Executive Offices) (Zip Code)(404)810-0089(Registrant’s Telephone Number, Including Area Code) Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.Yes☐No☒ Indicate by check mark if the Registrant is not required to file reports pursuant to Section13 or Section15(d) of the Act.Yes☐No☒ Indicate by check mark whether the Registrant (1)has filed all reports required to be filed by Section13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (orfor such shorter period that the registrant was required to file such reports), and (2)has been subject to such filing requirements for the past 90 days.Yes☒No☐Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of RegulationS-T(§232.405 of thischapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, anon-acceleratedfiler, a smaller reporting company or an emerging growth company. See thedefinitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule12b-2of the Exchange Act. Largeacceleratedfiler☐Acceleratedfiler☐Non-accelerated filer☒Smallerreportingcompany☒Emerginggrowthcompany☒ If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accountingstandards provided pursuant to Section13(a) of the Exchange Act.☐ Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the Registrant’s executiveofficers during the relevant recovery period pursuant to§240.10D-1(b).☐ Indicate by check mark whether the Registrant is a shell company (as defined in Rule12b-2of the Exchange Act).Yes☐No☒ The Registrant wasnot a public company as of the last business day of its most recently completed second fiscal quarter and, therefore, cannot calculate the aggregate market value of itscommon equity held bynon-affiliatesas of such date. The Registrant’s ClassA common stock began trading on the New York Stock Exchange on September26, 2024.As of March 15, 2025, there were issued and outstanding9,200,000shares of the Registrant’s ClassA common stock and54,087,158shares of the Registrant’s ClassB common stock.Documents incorporated by reference: Part III of this Annual Report on Form10-Kincorporates by reference certain information from the Registrant’s Definitive Proxy Statement for its 2025 Annual Meeting of Stockholders, tobe filed within 120 days after the end of the fiscal year to which this report relates. Table of Contents GUARDIAN PHARMACY SERVICES, INC. FORM10-K TABLE OF CONTENTS SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARYPART I Item 1. BusinessItem 1A. Risk FactorsItem 1B. Unresolved Staff CommentsItem 1C. CybersecurityItem 2. PropertiesItem 3. Legal ProceedingsItem 4. Mine Safety DisclosuresPART II Item 5. Market for the Company’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity SecuritiesItem 6. [Reserved]Item 7. Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 7A. Quantitative and Qualitative Disclosures About Market RiskItem 8. Financial Statements and Supplementary DataItem 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure PART III Item 10. Directors, Executive Officers and Corporate GovernanceItem 11. Executive CompensationItem 12. Security Ownership of Certain Beneficial Owners and Management and Related StockholdersItem 13. Certain Relationships and Related Party Transactions and Director IndependenceItem 14. Principal Accountant Fees and Services PART IV Item 15. Exhibits and Financial Statement SchedulesItem 16. Form10-KSummary Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKINGSTATEMENTS AND RISK FACTOR SUMMARY This Annual Report on Form10-Kcontains “forward-looking statements” within the meaning of Section27A of the Securities Act of 1933, asamended (the “Securities Act”), and Section21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-lookingstatements are all statements other than those of historical